MDT vs PODD: How Medtronic and Insulet Corporation Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MDT and PODD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MDT and PODD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans four main areas: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform), and Diabetes (insulin pumps and continuous glucose monitoring). The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics.

Full MDT guide

Insulet Corporation sells one thing extremely well. The Omnipod is a small adhesive pod worn on the body that holds insulin and delivers it without tubing, controlled by a phone app or a handheld. The current generation, Omnipod 5, is an automated insulin delivery system: it reads a continuous glucose monitor (Dexcom G7 or Abbott's FreeStyle Libre) and adjusts basal insulin automatically. The pods are disposable and replaced every three days, so the business is a classic razor-and-blade model where each new user converts into a predictable multi-year consumable stream. Insulet also distributes most of its US volume through the pharmacy channel rather than durable medical equipment, which lowers the friction of getting a patient started and has been a structural advantage over tubed competitors. A small drug delivery segment supplies pod technology to a pharmaceutical partner, but it is under ~2% of revenue and shrinking by design.

Full PODD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
• PODD drivers: Installed base compounding through pods; International expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. For PODD, type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes.

Pick MDT if you believe its drivers more; PODD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MDT and PODD guides.

MDT. Medtronic trades at a moderate valuation relative to faster-growing medtech peers, reflecting its scale, diversification, and reliable dividend but also a track record of slower organic growth. The multiple has expanded when new product cycles reaccelerated growth and compressed during periods of execution stumbles. The yield gives it a defensive, income-oriented profile within healthcare.

PODD. Insulet guided full-year 2026 revenue to roughly $3.2-3.3 billion with constant-currency growth of ~20-22%, trimmed from ~21-23%, and cut US Omnipod growth to ~17-19% while raising international to ~30-32%. The cut was small in dollars but changed the narrative, and the shares fell about 20% on August 5, 2026 to around $133 against a 52-week high of ~$355. At roughly 19x forward earnings the stock now prices in materially slower growth than it did a year earlier.

Headline figures (approximate, early 2026): MDT shows revenue (ttm) ~$33 billion, operating margin ~20% (non-GAAP higher; GAAP affected by amortization), net income (ttm) ~$4.5 billion, eps (ttm) ~$3.50 GAAP; non-GAAP higher; PODD shows revenue (ttm) ~$3.05B, q2 2026 revenue ~$802M, up ~23% year over year, adjusted gross margin (q2 2026) ~72.9%, net income / eps (ttm, gaap) ~$375M / ~$5.35.

MDT and PODD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MDT and PODD exposure against your real portfolio. It is not an investment adviser.